# Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome

> **NCT05306080** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 10 (estimated)

## Conditions studied

- CRS - Cytokine Release Syndrome
- HLH

## Interventions

- **DRUG:** Tadekinig alfa (IL-18BP)

## Key facts

- **NCT ID:** NCT05306080
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-17
- **Primary completion:** 2028-01
- **Final completion:** 2028-04
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05306080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05306080, "Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05306080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*